{
    "clinical_study": {
        "@rank": "109278", 
        "acronym": "FORWARD", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Arm 1: AS902330 (100 mcg)", 
                "arm_group_type": "Experimental", 
                "description": "AS902330 will be administered at a dose of 100 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years."
            }, 
            {
                "arm_group_label": "Treatment Arm 2 : AS902330 (100 mcg) alternating with placebo", 
                "arm_group_type": "Experimental", 
                "description": "AS902330, 100 mcg, will be administered in Cycles 1 and 3 and matching placebo will be administered in Cycles 2 and 4, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years."
            }, 
            {
                "arm_group_label": "Treatment Arm 3: AS902330 (30 mcg)", 
                "arm_group_type": "Experimental", 
                "description": "AS902330 will be administered at a dose of 30 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years."
            }, 
            {
                "arm_group_label": "Treatment Arm 4 : AS902330 (30 mcg) alternating with placebo", 
                "arm_group_type": "Experimental", 
                "description": "AS902330, 30 mcg, will be administered in Cycles 1 and 3 and matching placebo will be administered in Cycles 2 and 4, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years."
            }, 
            {
                "arm_group_label": "Arm 5: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching Placebo will be administered in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2\n      trial of AS902330 administered intra-articularly in subjects with primary osteoarthritis of\n      the knee and Kellgren-Lawrence Grade 2 or 3. The trial is intended to investigate the\n      efficacy and safety of different intra articular dosages of AS902330 (Sprifermin) in these\n      individuals."
        }, 
        "brief_title": "A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis, Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects will be equally randomized to either one of 4 treatment arms or a placebo arm. The\n      trial consists of a Screening period lasting up to 42 days, a two-year double-blind\n      placebo-controlled (DBPC) treatment phase, which begins  at randomization (Week 0) and ends\n      at Year 2, and a 3-year extended follow-up phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age from 40 to 85 years; of either sex\n\n          -  Primary femorotibial osteoarthritis according to American College of Rheumatology\n             (ACR) clinical and radiographic criteria , and meeting protocol-specified X-ray\n             criteria in the target knee at screening\n\n          -  Pain score in the target knee and/or the need for regular symptomatic treatment of\n             knee pain with paracetamol (acetaminophen), systemic non-steroidal anti-inflammatory\n             drugs (NSAIDs) including cyclooxygenase (COX)-2 selective inhibitors (coxibs), or\n             tramadol on most days in the  previous month (that is, more than half of the days in\n             the previous month)\n\n          -  A history of pain due to Osteoarthritis in the target knee for at least 6 months\n\n          -  A protocol-specified pain score for the target knee in response to Question 1 of the\n             WOMAC pain index (\"how much pain have you had [in the target knee, over the past 48\n             hours] when walking on a flat surface?\") after washout of at least 5 half-lives of\n             analgesic medication(s): acetaminophen, topical or oral NSAIDS, coxibs, opioids,\n             and/or tramadol\n\n          -  Women of childbearing potential must use a form of contraception with a failure rate\n             of less than 1 percent per year throughout the trial\n\n        Exclusion Criteria:\n\n          -  Malalignment of greater than 5 degrees in the femorotibial axis of the target knee\n\n          -  Clinical signs of inflammation (redness) in the target knee\n\n          -  Intra-articular administration of corticosteroids or hyaluronic acid into either knee\n             within 6 months before Screening\n\n          -  Planned knee surgery (affecting either the target or the contralateral knee) within\n             the next two years\n\n          -  Concomitant conditions or treatments deemed to be incompatible with trial\n             participation\n\n          -  Any contraindication to MRI according to MRI guidelines, including the inability to\n             undergo a knee MRI exam because of inability to fit in the scanner or knee coil\n\n          -  Pregnancy or breastfeeding\n\n          -  Participation in another clinical trial within the 30 days (or 5 half-lives of the\n             investigated compound, whichever is longer) before screening\n\n          -  Legal incapacity or limited legal capacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "549", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919164", 
            "org_study_id": "EMR700692_006", 
            "secondary_id": "2011-003059-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment Arm 1: AS902330 (100 mcg)", 
                "description": "AS902330 will be administered at a dose of 100 mcg  in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "AS902330 100 microgram (mcg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sprifermin", 
                    "Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)"
                ]
            }, 
            {
                "arm_group_label": "Treatment Arm 2 : AS902330 (100 mcg) alternating with placebo", 
                "description": "AS902330 will be administered at a dose of 100 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "AS902330 100 microgram (mcg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sprifermin", 
                    "rhFGF-18"
                ]
            }, 
            {
                "arm_group_label": "Treatment Arm 3: AS902330 (30 mcg)", 
                "description": "AS902330 will be administered at a dose of 30 mcg  in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "AS902330 30 microgram (mcg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sprifermin", 
                    "rhFGF-18"
                ]
            }, 
            {
                "arm_group_label": "Treatment Arm 4 : AS902330 (30 mcg) alternating with placebo", 
                "description": "AS902330 will be administered at a dose of 30 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "AS902330 30 microgram (mcg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sprifermin", 
                    "rhFGF-18"
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment Arm 2 : AS902330 (100 mcg) alternating with placebo", 
                    "Treatment Arm 4 : AS902330 (30 mcg) alternating with placebo"
                ], 
                "description": "Matching placebo will be administered in 2 cycles (at Months 6 and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 5: Placebo", 
                "description": "Matching placebo will be administered in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mitogens"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Osteoarthritis of knee", 
            "AS902330", 
            "Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)", 
            "Sprifermin", 
            "Placebo"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "To inquire about eligibility to participate in the study for non-US citizens, please go to www.ccbr.com and fill out the Join a trial NOW Questionnaire or simply click here", 
            "url": "http://www.ccbr.com/patient/en/2011-11-15-14-12-41"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pardubice", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vejle", 
                        "country": "Denmark"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Talinn", 
                        "country": "Estonia"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Research site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Czech Republic", 
                "Denmark", 
                "Estonia", 
                "Hong Kong", 
                "Poland", 
                "Romania"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Different Intra Articular (i.a.) Dosages of Sprifermin in Subjects With Primary Osteoarthritis of the Knee", 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Norma Muurahainen, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Medicines Agency", 
                "Estonia: The State Agency of Medicine", 
                "Czech Republic: State Institute for Drug Control", 
                "Romania: National Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Hong Kong: Department of Health", 
                "Argentina: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in cartilage thickness in the total femorotibial joint as evaluated by MRI at 2 years", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919164"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score and in the WOMAC pain, function, and stiffness index scores up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change from Baseline in the 20-meter walk test up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change from Baseline in the Patient's Global Assessment (PGA) up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change from Baseline in minimal joint space width (JSW) in the medial and lateral compartments as evaluated by X-ray up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change from Baseline in cartilage thickness in the medial and lateral compartments as well as in the total femorotibial joint up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Change from Baseline in cartilage volume in the medial and lateral compartments as well as in the total femorotibial joint up to 2 years", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Synovial fluid levels of AS902330", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Serum levels of AS902330", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Number of Subjects with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 260"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "collaborator": {
                "agency": "Nordic Bioscience Clinical Development AS, Herlev Denmark", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}